American Shared Hospital Services
AMS NYSE Services-Medical Laboratories Financials FY2016–FY2025
Last close · Oct 23, 2026
$1.26
0.0%What American Shared Hospital Services does
No business description yet.
- Legal name
- AMERICAN SHARED HOSPITAL SERVICES
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Accession · CIK
- 0001437749-26-010731
0000744825
Revenue and margins
American Shared Hospital Services had $28.1M of revenue in fiscal 2025, down 0.9% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$4.5M in fiscal 2025, −16.2% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
American Shared Hospital Services returned — to shareholders in fiscal 2025. The diluted share count fell 1.3%.
Balance sheet
Cash, debt and the ratios that show how comfortably American Shared Hospital Services can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $8.1M | $12.3M | $13.7M | $11.0M | $3.5M |
| Debt incl. finance leases | $15.7M | $13.7M | $13.3M | $20.4M | $17.4M |
| Net debt / EBITDA | 1.2x | 0.2x | −0.1x | 2.8x | 6.6x |
| Debt / equity | 0.8x | 0.6x | 0.6x | 0.8x | 0.7x |
| Interest coverage | 1.8x | 3.0x | 0.2x | −1.9x | −2.3x |
| Current ratio | 2.6x | 3.6x | 1.9x | 2.5x | 0.8x |
| Quick ratio | 2.6x | 3.6x | 1.9x | 2.5x | 0.8x |
| Total assets | $45.4M | $44.0M | $48.2M | $60.2M | $55.5M |
| Total liabilities | $21.2M | $18.3M | $21.9M | $30.2M | $27.8M |
| Shareholders' equity | $19.9M | $21.6M | $22.6M | $25.2M | $24.0M |
| Net debt (− = net cash) | $7.6M | $1.3M | −$0.4M | $9.4M | $13.9M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | ✓ | ✓ | ✓ | ✓ | ✕ | ✓ | ✓ | ✓ | ✓ | ✕ |
| Cash from operations is positive | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Return on assets rose | — | ✓ | ✕ | ✕ | ✕ | ✓ | ✓ | ✕ | ✓ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✕ | ✓ |
| Debt fell relative to assets | — | ✓ | ✓ | ✓ | ✕ | ✕ | ✓ | ✓ | ✕ | ✓ |
| Current ratio rose | — | ✓ | ✓ | ✓ | ✕ | ✓ | ✓ | ✕ | ✓ | ✕ |
| Share count didn't rise | — | ✕ | ✓ | ✕ | ✕ | ✓ | ✕ | ✕ | ✕ | ✓ |
| Gross margin rose | — | ✕ | ✕ | ✕ | ✕ | ✓ | ✓ | ✓ | ✕ | ✕ |
| Revenue rose relative to assets | — | ✓ | ✓ | ✓ | ✓ | ✕ | ✓ | ✕ | ✓ | ✓ |
| F-score | — / 3 | 7 / 9 | 7 / 9 | 6 / 9 | 3 / 9 | 7 / 9 | 8 / 9 | 5 / 9 | 5 / 9 | 5 / 9 |
| Accruals ratio | −12.3% | −10.0% | −12.2% | −13.3% | −34.5% | −13.6% | −13.2% | −11.1% | 3.7% | −8.0% |
| Altman Z'' | 1.12 | 1.38 | 1.53 | 2.00 | −0.74 | 2.63 | 3.86 | 2.69 | 2.61 | 0.05 |
10 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $18.7M | $19.6M | $19.7M | $20.6M | $17.8M | $17.6M | $19.7M | $21.3M | $28.3M | $28.1M |
| Gross profit | $8.8M | $8.7M | $7.5M | $6.9M | $4.5M | $6.7M | $8.4M | $9.3M | $9.2M | $5.1M |
| Operating income | $3.3M | $2.4M | $1.9M | $1.5M | −$9.5M | $1.4M | $2.4M | $0.3M | −$2.8M | −$3.6M |
| Interest expense | $1.7M | $1.9M | $1.6M | $1.3M | $1.1M | $0.7M | $0.8M | $1.1M | $1.5M | $1.6M |
| Pretax income | $3.2M | $1.8M | $2.1M | $1.6M | −$9.5M | $0.9M | $2.5M | $0.7M | $1.2M | −$3.2M |
| Income tax | $0.9M | −$1.1M | $0.5M | $0.1M | −$1.7M | $0.3M | $1.0M | $0.4M | −$0.3M | −$0.5M |
| Net income | $0.9M | $1.9M | $1.0M | $0.7M | −$7.1M | $0.2M | $1.3M | $0.6M | $2.2M | −$1.6M |
| Diluted EPS | $0.17 | $0.33 | $0.17 | $0.11 | −$1.14 | $0.03 | $0.21 | $0.10 | $0.33 | −$0.23 |
| Diluted shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | $8.4M | $7.9M | $8.1M | $8.0M | $9.7M | $6.3M | $7.2M | $5.7M | $0.2M | $3.1M |
| Capital expenditure | $1.0M | $0.8M | $1.6M | $1.0M | $0.5M | $1.7M | $0.4M | $6.3M | $7.9M | $7.6M |
| Free cash flow | $7.3M | $7.1M | $6.5M | $7.1M | $9.3M | $4.6M | $6.8M | −$0.6M | −$7.8M | −$4.5M |
| Depreciation and amortization | $6.3M | $6.7M | $6.8M | $7.4M | $7.0M | $5.0M | $4.8M | $5.2M | $6.2M | $5.7M |
| Stock-based compensation | $0.2M | $0.3M | $0.2M | $0.2M | $0.3M | $0.4M | $0.4M | $0.4M | $0.4M | $0.4M |
| Acquisitions | — | — | — | $0.0M | $2.1M | $0.0M | — | $0.0M | −$0.5M | $0.0M |
| Share buybacks | $0.0M | — | — | — | — | — | — | — | — | — |
| Dividends and buybacks | $0.0M | — | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||||
| Cash and short-term investments | $2.9M | $2.2M | $1.4M | $1.4M | $4.0M | $8.1M | $12.3M | $13.7M | $11.0M | $3.5M |
| Total debt | $7.3M | $6.1M | $5.5M | $3.5M | $5.1M | $15.7M | $13.7M | $13.3M | $20.4M | $17.4M |
| Finance lease liabilities | — | — | — | — | $8.9M | — | — | — | — | — |
| Current assets | $7.9M | $8.9M | $9.9M | $10.7M | $10.9M | $15.1M | $18.7M | $20.5M | $26.3M | $17.7M |
| Current liabilities | $8.7M | $9.0M | $9.5M | $8.2M | $12.4M | $5.9M | $5.2M | $10.8M | $10.4M | $23.4M |
| Property and equipment, net | $51.3M | $48.5M | $46.7M | $41.5M | $30.4M | — | — | — | — | — |
| Goodwill | — | — | — | $0.0M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M |
| Intangible assets | — | — | — | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M |
| Total assets | $60.6M | $58.2M | $57.5M | $53.8M | $43.7M | $45.4M | $44.0M | $48.2M | $60.2M | $55.5M |
| Total liabilities | $39.1M | $34.3M | $32.4M | $27.8M | $24.4M | $21.2M | $18.3M | $21.9M | $30.2M | $27.8M |
| Shareholders' equity | $21.5M | $23.9M | $25.1M | $26.0M | $19.3M | $19.9M | $21.6M | $22.6M | $25.2M | $24.0M |
| Margins | ||||||||||
| Gross margin | 47.0% | 44.3% | 38.0% | 33.6% | 25.0% | 38.2% | 42.4% | 43.8% | 32.4% | 18.0% |
| Operating margin | 17.6% | 12.3% | 9.4% | 7.5% | −53.1% | 7.7% | 12.3% | 1.3% | −9.9% | −12.8% |
| EBITDA margin | 51.4% | 46.5% | 44.0% | 43.5% | −14.0% | 35.9% | 36.5% | 25.5% | 11.9% | 7.6% |
| Net margin | 5.0% | 9.8% | 5.2% | 3.2% | −39.6% | 1.1% | 6.7% | 2.9% | 7.7% | −5.5% |
| FCF margin | 39.2% | 36.1% | 32.9% | 34.2% | 52.1% | 26.1% | 34.7% | −2.6% | −27.4% | −16.2% |
| Returns | ||||||||||
| Return on capital | 8.9% | 8.7% | 5.0% | 5.0% | −36.6% | 3.5% | 6.9% | 0.8% | −8.1% | −7.5% |
| Return on capital employed | 6.3% | 4.9% | 3.9% | 3.4% | −30.3% | 3.4% | 6.3% | 0.7% | −5.6% | −11.2% |
| Return on equity | 4.3% | 8.5% | 4.2% | 2.6% | −31.2% | 1.0% | 6.4% | 2.8% | 9.1% | −6.3% |
| Return on assets | 1.5% | 3.2% | 1.8% | 1.2% | −14.5% | 0.4% | 3.0% | 1.3% | 4.0% | −2.7% |
| Return on tangible equity | 4.3% | 8.1% | 4.1% | 2.5% | −39.4% | 1.0% | 6.5% | 2.9% | 9.2% | −6.8% |
| Growth | ||||||||||
| Revenue growth | — | 4.6% | 0.8% | 4.5% | −13.4% | −1.2% | 12.0% | 8.0% | 32.9% | −0.9% |
| Net income growth | — | 106.8% | −46.8% | −35.6% | −1,171.0% | — | 584.5% | −54.1% | 258.4% | −171.0% |
| EPS growth | — | 94.1% | −48.5% | −35.3% | −1,136.4% | — | 600.0% | −52.4% | 230.0% | −169.7% |
| FCF growth | — | −3.9% | −8.0% | 8.8% | 31.6% | −50.6% | 49.1% | −108.1% | — | — |
| Share count change | — | 5.4% | −0.5% | 1.3% | 4.2% | −2.0% | 4.0% | 1.4% | 4.8% | −1.3% |
| Financial health | ||||||||||
| Net debt / EBITDA | 0.5x | 0.4x | 0.5x | 0.2x | — | 1.2x | 0.2x | −0.1x | 2.8x | 6.6x |
| Debt / equity | 0.3x | 0.3x | 0.2x | 0.1x | 0.3x | 0.8x | 0.6x | 0.6x | 0.8x | 0.7x |
| Interest coverage | 1.9x | 1.3x | 1.1x | 1.2x | −9.0x | 1.8x | 3.0x | 0.2x | −1.9x | −2.3x |
| Current ratio | 0.9x | 1.0x | 1.0x | 1.3x | 0.9x | 2.6x | 3.6x | 1.9x | 2.5x | 0.8x |
| Quick ratio | 0.9x | 1.0x | 1.0x | 1.3x | 0.9x | 2.6x | 3.6x | 1.9x | 2.5x | 0.8x |
| Capital allocation | ||||||||||
| Capex / revenue | 5.6% | 4.1% | 8.0% | 4.8% | 2.6% | 9.5% | 2.0% | 29.4% | 28.0% | 27.2% |
| Stock comp / revenue | 1.1% | 1.7% | 1.1% | 1.1% | 1.7% | 2.4% | 2.0% | 1.8% | 1.3% | 1.4% |
| Payouts / FCF | 0.0% | — | — | — | — | — | — | — | — | — |
| Quality scores | ||||||||||
| Piotroski F-score | — | 7.0 | 7.0 | 6.0 | 3.0 | 7.0 | 8.0 | 5.0 | 5.0 | 5.0 |
| Altman Z'' | 1.1 | 1.4 | 1.5 | 2.0 | −0.7 | 2.6 | 3.9 | 2.7 | 2.6 | 0.0 |
| Accruals ratio | −12.3% | −10.0% | −12.2% | −13.3% | −34.5% | −13.6% | −13.2% | −11.1% | 3.7% | −8.0% |
Source: SEC EDGAR XBRL filings (CIK 0000744825). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.
